Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) is making significant strides in its transition from a development-stage biotechnology company to a commercial-stage entity, driven by the FDA-approved immunotherapy LYMPHIR(TM) and a robust late-stage pipeline. The company's strategic focus on addressing significant unmet medical needs in critical care and oncology has positioned it for multiple potential catalysts in the near term.
LYMPHIR(TM) (denileukin diftitox-cxdl), approved by the U.S. Food and Drug Administration in August 2024, is a targeted immunotherapy for adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. Since its commercial launch in December 2025, LYMPHIR has generated $5.6 million in net product revenue during the first six months of fiscal 2026, with gross margins of approximately 80%. This initial commercial success is underscored by payer coverage representing nearly 100% of covered commercial lives and 83% of targeted accounts achieving formulary inclusion or active review as of May 2026. The company has also begun expanding LYMPHIR's reach internationally, with an initial shipment to Europe announced in April 2026, and has reported repeat orders from initial accounts, indicating growing physician engagement.
Beyond its approved indication, Citius is exploring LYMPHIR's potential in additional oncology settings through investigator-initiated studies. Positive topline results from Phase 1 studies evaluating LYMPHIR in combination with pembrolizumab for recurrent or refractory gynecologic cancers and prior to CD19-directed CAR-T therapy in high-risk relapsed or refractory diffuse large B-cell lymphoma were reported in fiscal 2026, suggesting broader applicability and potential label expansion.
The company's late-stage pipeline includes Mino-Lok(R), an antibiotic lock solution designed to salvage central venous catheters in patients with catheter-related bloodstream infections (CRBSIs) and central line-associated bloodstream infections (CLABSIs). These infections are particularly serious in cancer and hemodialysis patients, and there are currently no FDA-approved therapies specifically indicated to salvage infected catheters. Mino-Lok met its primary and secondary endpoints in a completed Phase 3 pivotal superiority trial and has received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA. Following a Type C meeting, the company received guidance outlining a pathway to support a future New Drug Application submission. Investor materials estimate worldwide sales potential of approximately $1.8 billion for Mino-Lok.
Another key candidate is Halo-Lido (CITI-002), a proprietary topical formulation combining halobetasol and lidocaine for the symptomatic treatment of hemorrhoids. With approximately 10 million people in the U.S. reporting hemorrhoid symptoms annually and no FDA-approved prescription products for this indication, Halo-Lido could become the first of its kind if approved. The company completed a Phase 2b study in 2023 and has since met with the FDA to discuss next steps in its development program.
Citius is also advancing a stem cell platform based on induced pluripotent stem cell-derived mesenchymal stem cells (i-MSCs) for potential treatment of acute respiratory distress syndrome (ARDS), including lung injury associated with sepsis. Interim results from a proof-of-concept sheep model showed improvements in oxygenation, systemic shock, pulmonary vascular injury, and bacterial clearance compared with controls, warranting additional studies to inform future human clinical trials.
The company's leadership team brings extensive pharmaceutical experience, with CEO Leonard Mazur having founded and sold multiple pharmaceutical companies, and Executive Vice Chairman Myron Holubiak having served as president of Roche Laboratories. This expertise supports the strategy of advancing differentiated therapies from development through commercialization.
With LYMPHIR now generating commercial revenue and Mino-Lok, Halo-Lido, and the stem cell platform progressing through regulatory and development stages, Citius Pharmaceuticals is positioned to leverage multiple potential catalysts. The company's focus on critical-care and oncology indications with significant unmet medical needs, combined with its commercial infrastructure, underscores its potential for future growth and value creation. For more information, visit https://www.citiuspharma.com/.
